Cellphire Therapeutics

Cellphire Therapeutics is a biotechnology company developing next-generation therapies. The company is applying its proprietary cell stabilization technology to platelets to develop life-saving products. Its lead investigational product is Thrombosome®, a freeze-dried hemostatic agent derived from human platelets. Cellphire’s technology has potential applications across a wide range of medical uses, including trauma, wound care, imaging, targeted drug delivery, and regenerative medicine. This therapy offers long-term stability and faster treatment of bleeding. To date, donated platelets have had a shelf life of 5 to 7 days. However, our patented technology allows us to freeze-dry and stabilize platelets so they can last for years. Once approved, our investigational product Thrombosome® can be made available anytime, anywhere, to anyone.